Tonghua Dongbao Pharmaceutical Co.,Ltd. (China)

Tonghua Dongbao Pharmaceutical Co., Ltd is a company located in Tonghua, China. The company specializes in the production of traditional Chinese and Western medicine, biopharmaceuticals, and plastic building materials. It is recognized as a key high-tech enterprise under the Torch Program by the Ministry of Science and Technology. Tonghua Dongbao Pharmaceutical Co., Ltd and its major shareholder, Dongbao Group, have developed and launched a number of nationally recognized new drugs and flagship products such as "Zhen Naoning," "Dongbao Gantai Tablets," and "Naoxuekang Tablets." In the field of biopharmaceuticals, their product "Ganshulin" has filled a gap in the domestic market, making China one of the few countries, alongside the United States and Denmark, capable of producing genetically recombinant human insulin and glargine insulin. Currently, Tonghua Dongbao Pharmaceutical Co., Ltd is undertaking a key revitalization project in the old industrial base of Northeast China, with a total investment of 350 million yuan. The project involves the expansion of the second phase of the Dongbao gene recombinant human insulin production facility, which aims to introduce and install advanced foreign equipment. As a result, the company has become one of the domestic production bases for human insulin.